SEC Form 4 · accession 0001834411-26-000006
AbCellera Biologics Inc. · ABCL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Booth
Officer — Chief Financial Officer
Period of report
Jun 3, 2026
Accepted (ET)
Jun 3, 2026 · 2:23 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001703057
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jun 3, 2026 | M | 250,000 | $0.19 | A | 445,600 | D | |
| Common Shares | holding | — | — | — | 130,959 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share option (right to buy)F1 | $0.19 | Jun 3, 2026 | M | 250,000 | D | — | Jun 15, 2026 | Common Shares | 250,000 | 8,501,849 | D |
Explanation of responses
- F1The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.